n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

You Ask, Cramer Answers

Jim Cramer answers questions on SanDisk, Vonage and more.

Good News for Tysabri

An FDA panel endorses the drug for Crohn's disease.

Monday's Health Winners & Losers

Vivus climbs on a nod from the FDA.

FDA Questions Tysabri for Crohn's Disease

Shares of Biogen and Elan fall.

Friday's Health Winners & Losers

Intuitive Surgical climbs on raised guidance.

EU Rejects New Use for Tysabri

Elan and Biogen Idec plan to appeal.

You Ask, Cramer Answers

Jim Cramer answers questions on Whole Foods Market, Zoltek and more.

U.K. Group Endorses Tysabri

Biogen and Elan say NICE recommends the MS drug.

Feuerstein's Biotech-Stock Mailbag

The Novacea story, Millenium Pharmaceuticals potential and Satraplatin's impact.

Bet on Biotech's Grand Prize

A diversified holding of Alzheimer's drug developers could pay off big.

10 Biotech Stocks Facing FDA Judgment Day

These names have important regulatory hurdles ahead.

Tuesday's Health Winners & Losers

Qiagen rises on a licensing deal with Germany's Epigenomics.

S&P Record Proves Elusive

The index tries again for an all-time high, but finishes slightly lower.

Real Story: Celebration Interruptus

The S&P fails to set a new record, leading some to ask 'Is this it?' Plus, Adam Feuerstein on Elan's big move and ASCO leaks.

Is This It? Celebration Interruptus

The S&P fails to set a new high, leading some to declare a 'top' is in. Plus, Adam Feuerstein on Elan's big news and ASCO leaks.

Elan Surges on Drug Trial

The stock is up 15%.

Feuerstein's Biotech-Stock Mailbag

Dendreon's big date, the good and bad on Biomira and a Cougar worth stalking.

New Rituxan Route

Study results show that the drug might have promise in treating multiple sclerosis.

Tuesday's Health Winners & Losers

Poor earnings sink biotech and health care stocks such as Amgen.

Elan Posts Wider Loss

Revenue advances 31%.

Health Care Sector Funds Get a Checkup

TheStreet.com Ratings gives health care and biotech funds a clean bill of health.

Multinationals Move on Nanotech

Investors who haven't found a pure play may have to move up the food chain.

Wednesday's Health Winners & Losers

Avalon Pharmaceuticals is rising.

Monday's Health Winners & Losers

Merck is stronger.

Tuesday's Health Winners & Losers

Elan is falling.

Loss Narrows for Elan

The company remains hopeful about Tysabri.

Coming Week: Shopper Spotlight

Traders will zero in on consumer-level inflation, as well as earnings reports from major retailers.

Tuesday's Health Winners & Losers

Myriad Genetics is rising.

Monday's Health Winners & Losers

BioCryst Pharmaceuticals is rising.

Friday's Health Winners & Losers

Intuitive Surgical jumps.